Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy

Study Overview
=================
Brief Summary
-----------------
The estimation of the cardiovascular risk in the general population must take into account small renal disturbances, as the microalbuminuria. Conversely certain parameters of the cardiovascular risk influence the evolution of renal diseases, for example the arterial high blood pressure. The measure of the activity of the autonomous nervous system, and especially the quantification of its variability, is a means to estimate the cardiovascular risk. The investigators formulate the hypothesis that the variability of the autonomous nervous system is an additional clinical element for the evaluation of the evolutionary risk of renal diseases. The aim of this study is to compare the variability of the autonomous nervous system during the various evolutionary stages of the renal disease. The renal disease studied will be IgA nephropathy (IgNA). IgNA is a histologically defined glomerulonephritis (rela biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at list 1+) by immunofluorescence.

Official Title
-----------------
Autonomic Nervous System (ANS) Analysis According to Different Renal Function Stage in Immunoglobin A (IgA) Nephropathy

Conditions
-----------------
IGA Glomerulonephritis

Intervention / Treatment
-----------------
* Device: Holter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of IgNA biopsy-proven free, informed, express and written Exclusion Criteria: IgNA secondary to Henoch-Schonlein purpura (HSP) or Systemic Lupus Erythematosus or alcoholic cirrhosis current kidney transplantation Hypertension treated or not, Diseases interfering with ANS analysis: cardiac arrhythmia, beta-blocker therapy diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2<br>Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) >90 ml/min/1.73 m2 | Device: Holter<br>* measure of ANS in IgAN patients<br>|
| Experimental: IgAN with GFR 60-89 ml/min/1.73 m2<br>Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2 | Device: Holter<br>* measure of ANS in IgAN patients<br>|
| Experimental: IgAN with GFR 30-59 ml/min/1.73 m2<br>Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2 | Device: Holter<br>* measure of ANS in IgAN patients<br>|
| Experimental: IgAN with GFR 15-29 ml/min/1.73 m2<br>Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2 | Device: Holter<br>* measure of ANS in IgAN patients<br>|
| Experimental: IgAN with GFR < 15ml/min/1.73 m2<br>Measure of ANS by holter device in IgAN patients with GFR < 15ml/min/1.73 m2. | Device: Holter<br>* measure of ANS in IgAN patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Standard deviation of all R-R intervals (SDNN) | Comparison of Standard deviation of all R-R intervals (SDNN) between GFR category of IgNA | day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IGA Glomerulonephritis, Autonomic nervous system, ANS